To clarify the action mechanism of anti-PCSK9 antibody therapy for acute coronary syndrome

To clarify the action mechanism of anti-PCSK9 antibody therapy for acute coronary syndrome - To clarify the action mechanism of anti-PCSK9 antibody therapy for acute coronary syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030860

Enrollment

150

Registered

2018-03-01

Start date

2018-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute coronary syndrome

Interventions

PCSK9 inhibitors-treated and non-treated groups 3months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: a serum LDL-C level more than 70mg/dl, acute coronay syndrome, PCI with drug-eluting stent, age more than 20, participants have a statin

Exclusion criteria

Exclusion criteria: significant liver dysfunction(ALT more than 100 U/L), serum creatinine level more than 3 mg/dl, end-stage renal disease, a pregnancy or inability to provide written informed consent, Participants had already had anti-PCSK9 antibody on admission, participants had serious complication of PCI

Design outcomes

Primary

Measure	Time frame
Major adverse Cardiac and Cerebrovascular Events (all cause death, cardiovascular death, cerebrovascular accident, coronary revascularization etc)	—

Countries

Japan

Contacts

Public ContactYuichiro Maekawa

Hamamatsu University School of Medicine Internal Medicine III

ymaekawa@hama-med.ac.jp0534352111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026